ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome (RADAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00932100
Recruitment Status : Completed
First Posted : July 3, 2009
Last Update Posted : March 2, 2012
Sponsor:
Information provided by (Responsible Party):
Regado Biosciences, Inc.

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : January 2011
  Actual Study Completion Date : January 2011

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 May 29, 2013
July 25, 2013
Publications of Results:
TCT-176: Access and non-Access Site Bleeding in Acute Coronary Syndrome Patients Treated with a Novel Actively Reversible Factor IXa Inhibitor. Results from the RADAR Trial J Am Coll Cardiol 2011 58: B47

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):